ArticleScientific reports2025
PISTOL MRI allows noninvasive assessment of changes in tumor oxygenation post hypoxia targeted therapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combining Oxygen-Enhanced MRI and Electron Paramagnetic Resonance Oximetry for Quantitative OE-MRI (qOE-MRI) as a Method for Mapping Absolute Oxygen Levels (pOMagnetic resonance in medicine · 2026Article
- Toward noninvasive quantification of adipose tissue oxygenation with MRI.International journal of obesity (2005) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tumor hypoxia has been shown to promote tumor progression, cause resistance to both radiotherapy and chemotherapy and is a marker for poor prognosis. Due to its ability to modulate the clinical outcome, hypoxia has been recognized as a tumor-specific target for development of novel hypoxia-activated/targeted bioreductive pro-drugs. In the present study, a 1H MRI based pO2 measuring technique, PISTOL (Proton Imaging of Siloxanes to map Tissue Oxygenation Levels), was used to determine the baseline oxygenation of pre-clinical models of non-small cell lung cancer (NCI-H1975) and epidermoid carcinoma (A431) and their response to hypoxia-activated pro-drug (HAP) Tirapazamine (TPZ). A431 tumors had lower baseline oxygenation than the NCI-H1975 tumors (p < 0.05). TPZ was effective in slowing the tumor growth only in NCI-H1975 tumors, even though A431 tumors were significantly less oxygenated (50 ± 14 torr for NCI-H1975 vs. 30 ± 11 torr for A431, p < 0.0001) and had similar hypoxic fractions (0.08 ± 0.09 for NCI-H1975 vs. 0.18 ± 0.19 for A431, p > 0.05) pre-treatment.TPZ resulted in a significant decrease (p < 0.05) in the oxygenation of central regions of NCI-H1975 tumor, and an increase in the edema fraction which can be attributed to its reported anti-vascular effect. In conclusion, PISTOL was able to report the changes in tumor oxygenation in both the tumor xenografts over time and in response to therapy. The baseline mean pO2 and hypoxic fraction alone were not a reliable indicator of therapeutic efficacy and the results indicate that other factors (e.g. tumor perfusion and relative expression of nitroreductases) may play an important role in determining efficacy of hypoxia-targeted treatments in conjunction with tumor oxygenation status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.